Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Necuparanib, a multi-targeting heparan sulfate mimetic, targets tumor and stromal compartments in pancreatic cancer.

MacDonald A, Priess M, Curran J, Guess J, Farutin V, Oosterom I, Chu CL, Cochran E, Zhang L, Getchell K, Lolkema M, Schultes BC, Krause S.

Mol Cancer Ther. 2018 Nov 6. pii: molcanther.0417.2018. doi: 10.1158/1535-7163.MCT-18-0417. [Epub ahead of print]

PMID:
30401693
2.

Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors.

Mehla K, Tremayne J, Grunkemeyer JA, O'Connell KA, Steele MM, Caffrey TC, Zhu X, Yu F, Singh PK, Schultes BC, Madiyalakan R, Nicodemus CF, Hollingsworth MA.

Cancer Immunol Immunother. 2018 Mar;67(3):445-457. doi: 10.1007/s00262-017-2095-7. Epub 2017 Dec 4.

PMID:
29204701
3.

Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity.

Washburn N, Schwab I, Ortiz D, Bhatnagar N, Lansing JC, Medeiros A, Tyler S, Mekala D, Cochran E, Sarvaiya H, Garofalo K, Meccariello R, Meador JW 3rd, Rutitzky L, Schultes BC, Ling L, Avery W, Nimmerjahn F, Manning AM, Kaundinya GV, Bosques CJ.

Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1297-306. doi: 10.1073/pnas.1422481112. Epub 2015 Mar 2. Erratum in: Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):E4339.

4.

A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy.

Daniels-Wells TR, Helguera G, Leuchter RK, Quintero R, Kozman M, Rodríguez JA, Ortiz-Sánchez E, Martínez-Maza O, Schultes BC, Nicodemus CF, Penichet ML.

BMC Cancer. 2013 Apr 17;13:195. doi: 10.1186/1471-2407-13-195.

5.

Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells.

Daniels TR, Leuchter RK, Quintero R, Helguera G, Rodríguez JA, Martínez-Maza O, Schultes BC, Nicodemus CF, Penichet ML.

Cancer Immunol Immunother. 2012 Jul;61(7):991-1003. doi: 10.1007/s00262-011-1150-z. Epub 2011 Nov 30.

6.

Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Schultes BC, Smith LM, Nicodemus CF.

Clin Cancer Res. 2007 Jul 1;13(13):4026; author reply 4026-7. No abstract available.

7.

Role of monoclonal antibodies in tumor-specific immunity.

Nicodemus CF, Smith LM, Schultes BC.

Expert Opin Biol Ther. 2007 Mar;7(3):331-43. Review.

PMID:
17309325
8.

A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer.

Ehlen TG, Hoskins PJ, Miller D, Whiteside TL, Nicodemus CF, Schultes BC, Swenerton KD.

Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1023-34.

PMID:
16343178
9.

Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity.

de Bono JS, Rha SY, Stephenson J, Schultes BC, Monroe P, Eckhardt GS, Hammond LA, Whiteside TL, Nicodemus CF, Cermak JM, Rowinsky EK, Tolcher AW.

Ann Oncol. 2004 Dec;15(12):1825-33.

PMID:
15550589
10.

Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer.

Berek JS, Taylor PT, Gordon A, Cunningham MJ, Finkler N, Orr J Jr, Rivkin S, Schultes BC, Whiteside TL, Nicodemus CF.

J Clin Oncol. 2004 Sep 1;22(17):3507-16.

PMID:
15337799
11.

CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients.

Gordon AN, Schultes BC, Gallion H, Edwards R, Whiteside TL, Cermak JM, Nicodemus CF.

Gynecol Oncol. 2004 Aug;94(2):340-51.

PMID:
15297171
12.

Using antibodies in tumour immunotherapy.

Schultes BC, Nicodemus CF.

Expert Opin Biol Ther. 2004 Aug;4(8):1265-84. Review.

PMID:
15268661
13.

Monitoring of immune responses to CA125 with an IFN-gamma ELISPOT assay.

Schultes BC, Whiteside TL.

J Immunol Methods. 2003 Aug;279(1-2):1-15.

PMID:
12969543
14.

Immunomodulation with antibodies: clinical application in ovarian cancer and other malignancies.

Nicodemus CF, Schultes BC, Hamilton BL.

Expert Rev Vaccines. 2002 Jun;1(1):35-48. Review.

PMID:
12908511
15.

Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer.

Möbus VJ, Baum RP, Bolle M, Kreienberg R, Noujaim AA, Schultes BC, Nicodemus CF.

Am J Obstet Gynecol. 2003 Jul;189(1):28-36.

PMID:
12861134
16.

Biologic and immunologic therapies for ovarian cancer.

Berek JS, Schultes BC, Nicodemus CF.

J Clin Oncol. 2003 May 15;21(10 Suppl):168s-174s. Review.

PMID:
12743131
17.

Characterization of an anti-MUC1 monoclonal antibody with potential as a cancer vaccine.

Qi W, Schultes BC, Liu D, Kuzma M, Decker W, Madiyalakan R.

Hybrid Hybridomics. 2001;20(5-6):313-24.

PMID:
11839249
18.
19.

Immunotherapy of human ovarian carcinoma with OvaRex MAb-B43.13 in a human-PBL-SCID/BG mouse model.

Schultes BC, Zhang C, Xue LY, Noujaim AA, Madiyalakan R.

Hybridoma. 1999 Feb;18(1):47-55.

PMID:
10211788
20.

Summary report on the ISOBM TD-6 workshop: analysis of 20 monoclonal antibodies against Sialyl Lewisa and related antigens. Montreux, Switzerland, September 19-24, 1997.

Rye PD, Bovin NV, Vlasova EV, Molodyk AA, Baryshnikov A, Kreutz FT, Garinther WI, Schultes BC, Noujaim AA, Madiyalakan R, Magnani J, Nilsson O, Nilsson K, Nustad K, Norum L, Bell H, Cao Y, Suresh MR, Very DL, Freeman JV, Yeung KK, Hilgers J.

Tumour Biol. 1998;19(5):390-420.

PMID:
9701730
21.

Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1).

Schultes BC, Baum RP, Niesen A, Noujaim AA, Madiyalakan R.

Cancer Immunol Immunother. 1998 Jun;46(4):201-12.

PMID:
9671143
22.

OVAREX MAb-B43.13:IFN-gamma could improve the ovarian tumor cell sensitivity to CA125-specific allogenic cytotoxic T cells.

Madiyalakan R, Yang R, Schultes BC, Baum RP, Noujaim AA.

Hybridoma. 1997 Feb;16(1):41-5.

PMID:
9085127
23.

Idiotypic cascades after injection of the monoclonal antibody OC125. A study in a mouse model.

Schultes BC, Reinsberg J, Wagner U, Schlebusch H, Richter H, Krebs D, Biersack HJ.

Cell Biophys. 1994;24-25:259-66.

PMID:
7736531
25.

Purification and characterization of two different thymidine-5'-triphosphosphate-hydrolysing enzymes in human serum.

Schultes BC, Fischbach E, Dahlmann N.

Biol Chem Hoppe Seyler. 1992 May;373(5):237-47.

PMID:
1320895
26.

Supplemental Content

Loading ...
Support Center